Roivant Sciences Ltd. (NASDAQ:ROIV) Receives $13.00 Consensus Price Target from Brokerages

Roivant Sciences Ltd. (NASDAQ:ROIVGet Rating) has earned an average rating of “Buy” from the nine brokerages that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation and eight have issued a buy recommendation on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $13.33.

Several brokerages have commented on ROIV. Cantor Fitzgerald began coverage on Roivant Sciences in a research report on Friday. They set an “overweight” rating and a $15.00 price objective for the company. Zacks Investment Research lowered Roivant Sciences from a “hold” rating to a “sell” rating in a research report on Friday, February 18th.

Roivant Sciences stock traded down $0.17 on Monday, hitting $3.69. 376,691 shares of the stock traded hands, compared to its average volume of 463,058. The business’s fifty day simple moving average is $4.89 and its 200 day simple moving average is $7.31. Roivant Sciences has a 1 year low of $3.63 and a 1 year high of $16.76.

Roivant Sciences (NASDAQ:ROIVGet Rating) last announced its quarterly earnings data on Monday, February 14th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.18). The business had revenue of $24.34 million during the quarter, compared to analyst estimates of $10.13 million. Analysts predict that Roivant Sciences will post -1.29 earnings per share for the current year.

In related news, CAO Rakhi Kumar sold 7,281 shares of Roivant Sciences stock in a transaction dated Friday, March 25th. The stock was sold at an average price of $5.06, for a total value of $36,841.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Matthew Gline sold 92,324 shares of Roivant Sciences stock in a transaction dated Monday, March 7th. The stock was sold at an average price of $5.52, for a total value of $509,628.48. The disclosure for this sale can be found here. Insiders have sold 372,113 shares of company stock valued at $1,902,993 over the last 90 days.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. SB Investment Advisers UK Ltd. bought a new stake in Roivant Sciences in the 4th quarter worth about $1,001,706,000. BlackRock Inc. purchased a new stake in shares of Roivant Sciences during the 4th quarter valued at about $39,585,000. Geode Capital Management LLC purchased a new stake in shares of Roivant Sciences during the 4th quarter valued at about $11,694,000. Eventide Asset Management LLC purchased a new stake in shares of Roivant Sciences during the 4th quarter valued at about $6,703,000. Finally, Charles Schwab Investment Management Inc. purchased a new stake in shares of Roivant Sciences during the 4th quarter valued at about $6,967,000. Institutional investors own 16.63% of the company’s stock.

About Roivant Sciences (Get Rating)

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia.

Further Reading

Analyst Recommendations for Roivant Sciences (NASDAQ:ROIV)

Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.